IQVIA (NYSE:IQV) Hits New 12-Month High – What’s Next?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $271.80 and last traded at $260.6220, with a volume of 1197834 shares trading hands. The stock had previously closed at $267.77.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. Royal Bank Of Canada boosted their price objective on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Barclays reissued an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, BMO Capital Markets lifted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $243.62.

IQVIA Price Performance

The business has a 50-day simple moving average of $234.42 and a two-hundred day simple moving average of $194.81. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $42.33 billion, a price-to-earnings ratio of 31.91, a P/E/G ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 15,581 shares of company stock worth $3,796,021 in the last ninety days. Insiders own 1.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IQV. National Pension Service boosted its stake in shares of IQVIA by 6.6% during the 2nd quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock worth $72,646,000 after acquiring an additional 23,411 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of IQVIA during the second quarter worth $5,046,000. Engineers Gate Manager LP acquired a new stake in shares of IQVIA during the second quarter worth $632,000. SVB Wealth LLC boosted its position in shares of IQVIA by 7.4% in the 2nd quarter. SVB Wealth LLC now owns 4,349 shares of the medical research company’s stock valued at $840,000 after purchasing an additional 300 shares during the period. Finally, NewEdge Advisors LLC boosted its position in shares of IQVIA by 1.2% in the 2nd quarter. NewEdge Advisors LLC now owns 35,788 shares of the medical research company’s stock valued at $6,915,000 after purchasing an additional 420 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.